PharmaCyte Biotech submits IND to FDA for clinical trial in inoperable pancreatic cancer

This article was originally published here

PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, commented, “Submitting this IND is the most important milestone the Company has met thus far in the clinical development of our

The post PharmaCyte Biotech submits IND to FDA for clinical trial in inoperable pancreatic cancer appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply